首页 > 最新文献

Japanese journal of clinical oncology最新文献

英文 中文
Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study. 癌症恶病质患者改良格拉斯哥预后评分和预后营养指数与口服阿那莫林用药时间的关系:一项回顾性队列研究。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae086
Kazuma Fujita, Yumiko Akamine, Haruka Igarashi, Yayoi Fukushi, Katsuya Sasaki, Koji Fukuda, Masafumi Kikuchi, Hiroyuki Shibata

Background: The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin.

Methods: The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death.

Results: The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin.

Conclusion: Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.

背景:改良格拉斯哥预后评分(mGPS)和预后营养指数(PNI)是衡量癌症患者营养状况的指标;然而,基线mGPS和PNI对用于治疗癌症患者恶病质的胃泌素受体激动剂阿那莫瑞林用药时间的影响尚不清楚。本研究旨在阐明 mGPS 和 PNI 与口服阿那莫瑞林的持续时间之间的关系:主治医生根据癌症进展、疗效不佳、不良事件或死亡导致的停药情况决定口服阿那莫瑞林的持续时间:结果:口服阿莫瑞林 12 周的持续率为 30.4%。单变量分析表明,东部合作肿瘤学组表现状态(ECOG-PS)≥2(P 结论:ECOG-PS≥2 的患者可继续口服阿莫瑞林:与 mGPS 为 0 或 1 的患者相比,mGPS 为 2 的患者不太可能坚持口服阿莫瑞林治疗,无论 ECOG-PS 或同时接受化疗与否。因此,有必要考虑在 mGPS 为 0 或 1 时开始服用阿那莫瑞林。
{"title":"Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study.","authors":"Kazuma Fujita, Yumiko Akamine, Haruka Igarashi, Yayoi Fukushi, Katsuya Sasaki, Koji Fukuda, Masafumi Kikuchi, Hiroyuki Shibata","doi":"10.1093/jjco/hyae086","DOIUrl":"10.1093/jjco/hyae086","url":null,"abstract":"<p><strong>Background: </strong>The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin.</p><p><strong>Methods: </strong>The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death.</p><p><strong>Results: </strong>The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin.</p><p><strong>Conclusion: </strong>Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1165-1170"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Projection of the number of new lymphoma cases in the world. 全球新增淋巴瘤病例数量预测。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae147
Laureline Gatellier, Kayo Nakata
{"title":"Projection of the number of new lymphoma cases in the world.","authors":"Laureline Gatellier, Kayo Nakata","doi":"10.1093/jjco/hyae147","DOIUrl":"10.1093/jjco/hyae147","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1228-1229"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awareness, information sources, and beliefs regarding palliative care in the general population in Japan: a nationwide cross-sectional survey (INFORM study 2023). 日本普通民众对姑息关怀的认识、信息来源和信念:一项全国性横断面调查(INFORM 研究 2023)。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae092
Yu Uneno, Masanori Mori, Junko Saito, Aki Otsuki, Aya Kuchiba, Naomi Sakurai, Naoki Nakaya, Maiko Fujimori, Taichi Shimazu

Background: The diversification of information sources and changes in social structures necessitates updates on the state of public awareness of palliative care. Therefore, we clarified the status and determinants of awareness, information sources, and beliefs, regarding palliative care in Japan.

Methods: This nationwide cross-sectional survey included 10 000 participants aged ≥20 years enrolled through random sampling using a two-stage stratification in 2023. We used a mailed self-administered questionnaire (INFORM Study 2023). The questionnaire items were selected (partially modified) from the Health Information National Trends Survey (USA) to ensure comparability, included palliative care awareness, information sources, and beliefs. Weighted logistic regression was conducted to explore the determinants of awareness.

Results: Of the 3452 participants that responded (response rate: 35.3%), 65.2% had palliative care awareness. The weighted logistic regression analysis revealed that respondents less likely to have any palliative care awareness were younger, were male, had limited education history, had lower household income, and were non-Internet users. Of these, sex had the clear association (adjusted odds ratio for female vs. male: 3.20 [95% CI: 2.66-3.85]). Across all age groups, healthcare professionals (58.5%) and the Internet (30.5%) were the most trusted source of information. Younger participants frequently received information online. Most participants believed that palliative care was beneficial, although 82.0% associated it with death.

Conclusions: The Japanese population had a relatively high palliative care awareness, with the majority trusting information from healthcare professionals rather than the Internet. Further efforts are warranted to address barriers to receiving trustworthy palliative care information.

背景:随着信息来源的多样化和社会结构的变化,有必要更新公众对姑息关怀的认识状况。因此,我们阐明了日本公众对姑息关怀的认识、信息来源和信念的现状及决定因素:这项全国性横断面调查在 2023 年通过两阶段分层随机抽样的方式纳入了 10 000 名年龄≥20 岁的参与者。我们使用邮寄的自填式问卷(INFORM 研究 2023)。问卷项目选自(部分修改)美国健康信息全国趋势调查,以确保可比性,包括姑息关怀意识、信息来源和信念。研究人员采用加权逻辑回归法来探讨认知度的决定因素:在 3452 名回复者(回复率:35.3%)中,65.2% 具有姑息关怀意识。加权逻辑回归分析表明,较少具有姑息关怀意识的受访者年龄较小、为男性、受教育经历有限、家庭收入较低且不使用互联网。其中,性别具有明显的相关性(女性与男性的调整赔率比:3.20 [95% CI:2.66-3.85])。在所有年龄组中,医护人员(58.5%)和互联网(30.5%)是最值得信赖的信息来源。年轻的参与者经常从网上获取信息。大多数参与者认为姑息关怀是有益的,尽管 82.0% 的人将姑息关怀与死亡联系在一起:日本人对姑息关怀的认知度相对较高,大多数人相信医疗保健专业人员提供的信息,而不是互联网。有必要进一步努力,以解决获得值得信赖的姑息关怀信息的障碍。
{"title":"Awareness, information sources, and beliefs regarding palliative care in the general population in Japan: a nationwide cross-sectional survey (INFORM study 2023).","authors":"Yu Uneno, Masanori Mori, Junko Saito, Aki Otsuki, Aya Kuchiba, Naomi Sakurai, Naoki Nakaya, Maiko Fujimori, Taichi Shimazu","doi":"10.1093/jjco/hyae092","DOIUrl":"10.1093/jjco/hyae092","url":null,"abstract":"<p><strong>Background: </strong>The diversification of information sources and changes in social structures necessitates updates on the state of public awareness of palliative care. Therefore, we clarified the status and determinants of awareness, information sources, and beliefs, regarding palliative care in Japan.</p><p><strong>Methods: </strong>This nationwide cross-sectional survey included 10 000 participants aged ≥20 years enrolled through random sampling using a two-stage stratification in 2023. We used a mailed self-administered questionnaire (INFORM Study 2023). The questionnaire items were selected (partially modified) from the Health Information National Trends Survey (USA) to ensure comparability, included palliative care awareness, information sources, and beliefs. Weighted logistic regression was conducted to explore the determinants of awareness.</p><p><strong>Results: </strong>Of the 3452 participants that responded (response rate: 35.3%), 65.2% had palliative care awareness. The weighted logistic regression analysis revealed that respondents less likely to have any palliative care awareness were younger, were male, had limited education history, had lower household income, and were non-Internet users. Of these, sex had the clear association (adjusted odds ratio for female vs. male: 3.20 [95% CI: 2.66-3.85]). Across all age groups, healthcare professionals (58.5%) and the Internet (30.5%) were the most trusted source of information. Younger participants frequently received information online. Most participants believed that palliative care was beneficial, although 82.0% associated it with death.</p><p><strong>Conclusions: </strong>The Japanese population had a relatively high palliative care awareness, with the majority trusting information from healthcare professionals rather than the Internet. Further efforts are warranted to address barriers to receiving trustworthy palliative care information.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1171-1179"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. 转移性阉割敏感性前列腺癌患者三联疗法疗效的现实证据:一项日本多中心研究。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae098
Fumihiko Urabe, Yu Imai, Yuma Goto, Kojiro Tashiro, Masaki Hashimoto, Kentaro Yoshihara, Shutaro Yamamoto, Shuhei Hara, Keiichiro Miyajima, Wataru Fukuokaya, Yuki Enei, Kosuke Iwatani, Sotaro Kayano, Taro Igarashi, Koichi Aikawa, Takafumi Yanagisawa, Shoji Kimura, Shunsuke Tsuzuki, Masaya Murakami, Kenichi Hata, Tatsuya Shimomura, Hiroki Yamada, Jun Miki, Takahiro Kimura

Background: Two randomized trials demonstrated that the survival benefits afforded by triplet therapy were greater than those of doublet therapy, thus changing the treatment paradigm for metastatic castration-sensitive prostate cancer (mCSPC). This is the first study to assess the real-world use, performance, and safety of triplet therapy in Japanese patients.

Methods: This retrospective multicenter study included 45 consecutive mCSPC patients who received triplet therapy composed of androgen deprivation therapy (ADT), docetaxel, and darolutamide between January 2023 and June 2024. Baseline patient characteristics and their clinical parameters during triplet therapy were collected. Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events version 5.0, and imaging responses were evaluated following the RECIST criteria. The prostate-specific antigen (PSA) nadir was defined as the lowest PSA value during follow-up, and the PSA decrease was the initial PSA value minus the PSA nadir.

Results: The median patient age was 70 years and the median follow-up duration was 10 months. High-volume disease was present in 82.2% of patients. Concurrent administration of docetaxel and darolutamide was scheduled for 22.2% of cases. The incidence of any AE was 86.7%, with 55.5% of patients experiencing grade 3-4 AEs. Neutropenia was common, but prophylactic granulocyte colony-stimulating factor (G-CSF) significantly reduced the incidence of neutropenia of grade 3 or higher. Febrile neutropenia occurred in four patients (8.9%); these patients had not received prophylactic G-CSF. A decline in PSA of 90% was observed in 95.6% of patients, and an imaging response was seen in 97.8%.

Conclusions: Triplet therapy with ADT, darolutamide, and docetaxel was highly efficacious and tolerable in Japanese mCSPC patients, particularly those with high-volume disease. Prophylactic G-CSF prescription is crucial to manage neutropenia effectively. Further studies with longer follow-ups are needed to confirm these findings and explore the long-term outcomes.

背景:两项随机试验表明,三联疗法带来的生存益处大于双联疗法,从而改变了转移性阉割敏感性前列腺癌(mCSPC)的治疗模式。这是第一项评估三联疗法在日本患者中的实际使用情况、效果和安全性的研究:这项回顾性多中心研究纳入了 45 名连续的 mCSPC 患者,他们在 2023 年 1 月至 2024 年 6 月期间接受了由雄激素剥夺疗法(ADT)、多西他赛和达罗鲁胺组成的三联疗法。研究人员收集了患者的基线特征及其在三联疗法期间的临床参数。不良事件(AEs)按照《不良事件通用术语标准》5.0版进行分级,成像反应按照RECIST标准进行评估。前列腺特异性抗原(PSA)最低值定义为随访期间的最低PSA值,PSA下降值为初始PSA值减去PSA最低值:患者年龄中位数为 70 岁,随访时间中位数为 10 个月。82.2%的患者存在高体积疾病。22.2%的病例计划同时服用多西他赛和达罗他胺。任何AE的发生率为86.7%,其中55.5%的患者出现3-4级AE。中性粒细胞减少症很常见,但预防性粒细胞集落刺激因子(G-CSF)可显著降低3级或以上中性粒细胞减少症的发生率。有四名患者(8.9%)出现了发热性中性粒细胞减少症;这些患者未接受预防性 G-CSF。95.6%的患者PSA下降了90%,97.8%的患者出现了影像学反应:ADT、darolutamide和多西他赛三联疗法对日本mCSPC患者疗效显著,耐受性好,尤其是那些高体积疾病患者。预防性 G-CSF 处方对于有效控制中性粒细胞减少症至关重要。要证实这些研究结果并探讨其长期疗效,还需要进行更长时间的随访研究。
{"title":"Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.","authors":"Fumihiko Urabe, Yu Imai, Yuma Goto, Kojiro Tashiro, Masaki Hashimoto, Kentaro Yoshihara, Shutaro Yamamoto, Shuhei Hara, Keiichiro Miyajima, Wataru Fukuokaya, Yuki Enei, Kosuke Iwatani, Sotaro Kayano, Taro Igarashi, Koichi Aikawa, Takafumi Yanagisawa, Shoji Kimura, Shunsuke Tsuzuki, Masaya Murakami, Kenichi Hata, Tatsuya Shimomura, Hiroki Yamada, Jun Miki, Takahiro Kimura","doi":"10.1093/jjco/hyae098","DOIUrl":"10.1093/jjco/hyae098","url":null,"abstract":"<p><strong>Background: </strong>Two randomized trials demonstrated that the survival benefits afforded by triplet therapy were greater than those of doublet therapy, thus changing the treatment paradigm for metastatic castration-sensitive prostate cancer (mCSPC). This is the first study to assess the real-world use, performance, and safety of triplet therapy in Japanese patients.</p><p><strong>Methods: </strong>This retrospective multicenter study included 45 consecutive mCSPC patients who received triplet therapy composed of androgen deprivation therapy (ADT), docetaxel, and darolutamide between January 2023 and June 2024. Baseline patient characteristics and their clinical parameters during triplet therapy were collected. Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events version 5.0, and imaging responses were evaluated following the RECIST criteria. The prostate-specific antigen (PSA) nadir was defined as the lowest PSA value during follow-up, and the PSA decrease was the initial PSA value minus the PSA nadir.</p><p><strong>Results: </strong>The median patient age was 70 years and the median follow-up duration was 10 months. High-volume disease was present in 82.2% of patients. Concurrent administration of docetaxel and darolutamide was scheduled for 22.2% of cases. The incidence of any AE was 86.7%, with 55.5% of patients experiencing grade 3-4 AEs. Neutropenia was common, but prophylactic granulocyte colony-stimulating factor (G-CSF) significantly reduced the incidence of neutropenia of grade 3 or higher. Febrile neutropenia occurred in four patients (8.9%); these patients had not received prophylactic G-CSF. A decline in PSA of 90% was observed in 95.6% of patients, and an imaging response was seen in 97.8%.</p><p><strong>Conclusions: </strong>Triplet therapy with ADT, darolutamide, and docetaxel was highly efficacious and tolerable in Japanese mCSPC patients, particularly those with high-volume disease. Prophylactic G-CSF prescription is crucial to manage neutropenia effectively. Further studies with longer follow-ups are needed to confirm these findings and explore the long-term outcomes.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1208-1213"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing alimentary tract radiation in liver cancer treatment with proton beam therapy: a PET/CT imaging study. 评估肝癌质子束治疗中的消化道辐射:PET/CT 成像研究。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae085
Sachika Shiraishi, Masashi Yamanaka, Shintaro Shiba, Koichi Tokuuye

Background: Proton beams deposit energy along their path, abruptly stopping and generating various radioactive particles, including positrons, along their trajectory. In comparison with traditional proton beam therapy, scanning proton beam therapy is effective in delivering proton beams to irregularly shaped tumors, reducing excessive radiation exposure to the alimentary tract during the treatment of liver cancer.

Methods: In this study, we utilized positron emission tomography/computed tomography (PET/CT) imaging to assess the total amount of radiation to the alimentary tract during liver cancer treatment with proton beam therapy, involving the administration of complex irradiation in 13 patients.

Results: This approach resulted in the prevention of excess radiation. The planned radiation restraint doses for the colon exhibited a significant correlation with the PET values of the colon (correlation coefficient 0.8384, P = .0003). Likewise, the scheduled radiation restraint doses for the gastroduodenum were correlated with the PET values of the gastroduodenum (correlation coefficient 0.5397, P = .0569).

Conclusions: PET/CT conducted after proton beam therapy is useful for evaluating excess radiation in the alimentary tract. Proton beam therapy in liver cancer, assessed via PET/CT, effectively reduced alimentary tract radiation, which is vital for optimizing treatments and preventing excess exposure.

背景:质子束沿其轨迹沉积能量,突然停止并产生各种放射性粒子,包括正电子。与传统的质子束疗法相比,扫描质子束疗法能有效地将质子束投射到形状不规则的肿瘤上,减少肝癌治疗过程中消化道受到的过量辐射:在这项研究中,我们利用正电子发射断层扫描/计算机断层扫描(PET/CT)成像技术评估了13名患者在接受质子束疗法治疗肝癌期间消化道所受的辐射总量,其中包括复合照射:结果:这一方法避免了过量辐射。结肠的计划限制辐射剂量与结肠 PET 值有显著相关性(相关系数 0.8384,P = 0.0003)。同样,胃十二指肠的计划辐射抑制剂量与胃十二指肠的 PET 值也有相关性(相关系数 0.5397,P = .0569):结论:质子束治疗后进行的 PET/CT 可用于评估消化道的过量辐射。通过 PET/CT 评估肝癌质子束治疗可有效减少消化道辐射,这对优化治疗和防止辐射过量至关重要。
{"title":"Assessing alimentary tract radiation in liver cancer treatment with proton beam therapy: a PET/CT imaging study.","authors":"Sachika Shiraishi, Masashi Yamanaka, Shintaro Shiba, Koichi Tokuuye","doi":"10.1093/jjco/hyae085","DOIUrl":"10.1093/jjco/hyae085","url":null,"abstract":"<p><strong>Background: </strong>Proton beams deposit energy along their path, abruptly stopping and generating various radioactive particles, including positrons, along their trajectory. In comparison with traditional proton beam therapy, scanning proton beam therapy is effective in delivering proton beams to irregularly shaped tumors, reducing excessive radiation exposure to the alimentary tract during the treatment of liver cancer.</p><p><strong>Methods: </strong>In this study, we utilized positron emission tomography/computed tomography (PET/CT) imaging to assess the total amount of radiation to the alimentary tract during liver cancer treatment with proton beam therapy, involving the administration of complex irradiation in 13 patients.</p><p><strong>Results: </strong>This approach resulted in the prevention of excess radiation. The planned radiation restraint doses for the colon exhibited a significant correlation with the PET values of the colon (correlation coefficient 0.8384, P = .0003). Likewise, the scheduled radiation restraint doses for the gastroduodenum were correlated with the PET values of the gastroduodenum (correlation coefficient 0.5397, P = .0569).</p><p><strong>Conclusions: </strong>PET/CT conducted after proton beam therapy is useful for evaluating excess radiation in the alimentary tract. Proton beam therapy in liver cancer, assessed via PET/CT, effectively reduced alimentary tract radiation, which is vital for optimizing treatments and preventing excess exposure.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1180-1184"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. 尿路癌患者对恩福单抗维多汀的反应与周围神经病变之间的关系:一项多中心回顾性研究。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae082
Nozomi Hayakawa, Eiji Kikuchi, Go Kaneko, Ryo Yamashita, Daiki Ikarashi, Yuki Endo, Kimitsugu Usui, Wataru Obara, Masafumi Oyama, Yukihiro Kondo

Background: Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated.

Methods: We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0 months. We retrospectively analyzed the efficacy and safety of EV.

Results: The median age of the patients was 71 years old, 39% had PS of 1 or more, and 56.7% had primary tumor in upper urinary tract. Overall response rate (ORR) to EV therapy, median progression-free survival (PFS), and overall survival (OS) were 43.3%, 7.52 months, and 12.78 months, respectively. Any grade of treatment-related skin disorder, dysgeusia, peripheral neuropathy, gastrointestinal disorder, and hyperglycemia occurred in 61 (62.9%), 36 (37.1%), 34 (35.1%), 29 (29.9%), and 18 (18.6%) patients, respectively. The patients with EV-associated peripheral neuropathy had significantly higher ORR (58.8% vs. 34.9%, P = .032) and longer median PFS (8.05 vs. 6.31 months, P = .017) and OS (not reached vs. 11.57 months, P = .008, respectively) than those without. The occurrence of peripheral neuropathy after EV treatment and the presence of peritoneal dissemination were factors independently associated with PFS (hazard ratio = 0.46, P = .008 and hazard raito = 3.83, P = .004, respectively) and OS (hazard ratio = 0.30, P = .005 and hazard raito = 4.53, P = .002, respectively).

Conclusions: The occurrence of EV-related peripheral neuropathy might be associated with the efficacy of EV therapy in mUC patients.

背景:日本于2021年9月批准恩福单抗维多汀(EV)用于抗癌治疗后病情进展的转移性尿路上皮癌(mUC)患者。EV相关副作用的发生与临床结果之间的关系仍有待阐明:我们确定了自批准之日起至 2023 年 3 月在我们的五家机构接受 EV 治疗的 97 例 mUC 患者。中位随访时间为 7.0 个月。我们对 EV 的疗效和安全性进行了回顾性分析:患者的中位年龄为 71 岁,39% 的患者 PS 值为 1 或以上,56.7% 的患者原发肿瘤位于上尿路。EV治疗总反应率(ORR)、中位无进展生存期(PFS)和总生存期(OS)分别为43.3%、7.52个月和12.78个月。61例(62.9%)、36例(37.1%)、34例(35.1%)、29例(29.9%)和18例(18.6%)患者分别出现了任何级别的治疗相关皮肤病、口腔溃疡、周围神经病变、胃肠功能紊乱和高血糖。EV相关周围神经病变患者的ORR(58.8% vs. 34.9%,P = .032)显著高于无EV相关周围神经病变患者,中位PFS(8.05个月 vs. 6.31个月,P = .017)和OS(未达标 vs. 11.57个月,P = .008)分别长于无EV相关周围神经病变患者。EV治疗后发生周围神经病变和出现腹膜播散是与PFS(危险比分别为0.46,P = .008和Hazard raito = 3.83,P = .004)和OS(危险比分别为0.30,P = .005和Hazard raito = 4.53,P = .002)独立相关的因素:结论:EV相关周围神经病变的发生可能与MUC患者的EV疗效有关。
{"title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study.","authors":"Nozomi Hayakawa, Eiji Kikuchi, Go Kaneko, Ryo Yamashita, Daiki Ikarashi, Yuki Endo, Kimitsugu Usui, Wataru Obara, Masafumi Oyama, Yukihiro Kondo","doi":"10.1093/jjco/hyae082","DOIUrl":"10.1093/jjco/hyae082","url":null,"abstract":"<p><strong>Background: </strong>Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated.</p><p><strong>Methods: </strong>We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0 months. We retrospectively analyzed the efficacy and safety of EV.</p><p><strong>Results: </strong>The median age of the patients was 71 years old, 39% had PS of 1 or more, and 56.7% had primary tumor in upper urinary tract. Overall response rate (ORR) to EV therapy, median progression-free survival (PFS), and overall survival (OS) were 43.3%, 7.52 months, and 12.78 months, respectively. Any grade of treatment-related skin disorder, dysgeusia, peripheral neuropathy, gastrointestinal disorder, and hyperglycemia occurred in 61 (62.9%), 36 (37.1%), 34 (35.1%), 29 (29.9%), and 18 (18.6%) patients, respectively. The patients with EV-associated peripheral neuropathy had significantly higher ORR (58.8% vs. 34.9%, P = .032) and longer median PFS (8.05 vs. 6.31 months, P = .017) and OS (not reached vs. 11.57 months, P = .008, respectively) than those without. The occurrence of peripheral neuropathy after EV treatment and the presence of peritoneal dissemination were factors independently associated with PFS (hazard ratio = 0.46, P = .008 and hazard raito = 3.83, P = .004, respectively) and OS (hazard ratio = 0.30, P = .005 and hazard raito = 4.53, P = .002, respectively).</p><p><strong>Conclusions: </strong>The occurrence of EV-related peripheral neuropathy might be associated with the efficacy of EV therapy in mUC patients.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1194-1200"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of glioma recurrence using 18F-FAPI-04 and 18F-PSMA-1007 PET/CT. 使用 18F-FAPI-04 和 18F-PSMA-1007 PET/CT 诊断胶质瘤复发。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae087
Jingyu Fu, Daiyun Peng, Ying Zhang, Jiangyan Liu
{"title":"Diagnosis of glioma recurrence using 18F-FAPI-04 and 18F-PSMA-1007 PET/CT.","authors":"Jingyu Fu, Daiyun Peng, Ying Zhang, Jiangyan Liu","doi":"10.1093/jjco/hyae087","DOIUrl":"10.1093/jjco/hyae087","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1224-1225"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous thromboembolism in patients undergoing surgery for lung cancer: a post hoc analysis of the Cancer-VTE Registry. 肺癌手术患者的静脉血栓栓塞症:对癌症-VTE登记处的事后分析。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae090
Riken Kawachi, Tetsuya Okano, Nobuyasu Awano, Masaru Matsumoto, Jun Hosokawa, Atsushi Takita, Mari S Oba, Hideo Kunitoh

The relationship between lung cancer surgery and venous thromboembolism (VTE) in Japan has not been elucidated. This was a post hoc analysis of the Cancer-VTE Registry. The 1057 patients who underwent surgery for lung cancer were divided into the surgery alone (SA) group (n = 598) and the surgery plus chemotherapy (SC) group (n = 459), and the 1-year incidences of VTE and cerebral ischemia were analyzed. In the SA and SC groups, composite VTE was observed in one (0.2%) and 15 (3.3%) patients, respectively, and cerebral ischemia was observed in eight (1.3%) and four (0.9%) patients, respectively. Lymph node metastasis was more common in patients with D-dimer >1.2 μg/ml (odds ratio: 1.781, P = .004). SA had a low risk of VTE but a high risk of cerebral ischemia. Chemotherapy increases the risk of VTE. The D-dimer level was related to VTE and advanced cancer.

日本尚未阐明肺癌手术与静脉血栓栓塞(VTE)之间的关系。这是对癌症-VTE 登记进行的一项事后分析。1057 名接受肺癌手术的患者被分为单纯手术(SA)组(598 人)和手术加化疗(SC)组(459 人),并分析了 VTE 和脑缺血的 1 年发病率。在SA组和SC组中,分别有1例(0.2%)和15例(3.3%)患者出现复合VTE,分别有8例(1.3%)和4例(0.9%)患者出现脑缺血。淋巴结转移在D-二聚体大于1.2 μg/ml的患者中更为常见(几率比:1.781,P = .004)。SA发生VTE的风险较低,但发生脑缺血的风险较高。化疗会增加 VTE 的风险。D-二聚体水平与 VTE 和晚期癌症有关。
{"title":"Venous thromboembolism in patients undergoing surgery for lung cancer: a post hoc analysis of the Cancer-VTE Registry.","authors":"Riken Kawachi, Tetsuya Okano, Nobuyasu Awano, Masaru Matsumoto, Jun Hosokawa, Atsushi Takita, Mari S Oba, Hideo Kunitoh","doi":"10.1093/jjco/hyae090","DOIUrl":"10.1093/jjco/hyae090","url":null,"abstract":"<p><p>The relationship between lung cancer surgery and venous thromboembolism (VTE) in Japan has not been elucidated. This was a post hoc analysis of the Cancer-VTE Registry. The 1057 patients who underwent surgery for lung cancer were divided into the surgery alone (SA) group (n = 598) and the surgery plus chemotherapy (SC) group (n = 459), and the 1-year incidences of VTE and cerebral ischemia were analyzed. In the SA and SC groups, composite VTE was observed in one (0.2%) and 15 (3.3%) patients, respectively, and cerebral ischemia was observed in eight (1.3%) and four (0.9%) patients, respectively. Lymph node metastasis was more common in patients with D-dimer >1.2 μg/ml (odds ratio: 1.781, P = .004). SA had a low risk of VTE but a high risk of cerebral ischemia. Chemotherapy increases the risk of VTE. The D-dimer level was related to VTE and advanced cancer.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1219-1223"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options. 皮肤腺分泌癌综述:流行病学、诊断、预后和治疗方案。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae103
Seiji Tsuruta, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki

Cutaneous apocrine carcinoma is a rare skin cancer arising from apocrine sweat glands. Disease-specific treatments are required for cutaneous adnexal carcinomas due to their heterogeneous treatment responsiveness. This review reports on the epidemiology, diagnosis, pathological features, surgical management, and use of systemic therapies for cutaneous apocrine carcinoma. Diagnosing cutaneous apocrine carcinoma requires presenting with distinctive pathological features and excluding metastatic adenocarcinomas, particularly breast cancer. Clinical findings are essential to exclude metastatic adenocarcinomas, and immunohistochemistry can be used as an adjunctive tool to rule out other diseases. Wide local excision is the standard treatment for resectable cutaneous apocrine carcinomas. Prophylactic lymphadenectomy should be considered as a treatment option given the high incidence of lymph node metastasis. Generally, cutaneous apocrine carcinomas are resistant to chemotherapy and radiation therapy; however, adjuvant radiotherapy is recommended for high-risk patients. Radiation or systemic therapy is administered to patients with distant metastases or recurrence. The systemic therapeutic options include cytotoxic chemotherapy, hormonal therapy, targeted therapy, and immune checkpoint inhibitors. Given the lack of data on clinical prognosis and standardized treatments, further studies are needed to improve our understanding of cutaneous apocrine carcinomas.

皮肤附属腺癌是一种罕见的皮肤癌,源于附属汗腺。由于皮肤附件癌的治疗反应不一,因此需要针对具体疾病的治疗方法。本综述报告了皮肤附属腺癌的流行病学、诊断、病理特征、手术治疗和系统疗法的使用。诊断皮肤腺分泌癌需要具备独特的病理特征,并排除转移性腺癌,尤其是乳腺癌。临床发现是排除转移性腺癌的关键,免疫组化可作为排除其他疾病的辅助工具。局部广泛切除术是可切除皮肤腺癌的标准治疗方法。鉴于淋巴结转移的高发率,预防性淋巴结切除术应被视为一种治疗选择。一般来说,皮肤腺癌对化疗和放疗有抵抗力,但建议对高危患者进行辅助放疗。有远处转移或复发的患者可接受放射治疗或全身治疗。全身治疗方案包括细胞毒化疗、激素治疗、靶向治疗和免疫检查点抑制剂。由于缺乏有关临床预后和标准化治疗的数据,我们需要开展进一步的研究,以加深对皮肤腺分泌癌的了解。
{"title":"A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options.","authors":"Seiji Tsuruta, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki","doi":"10.1093/jjco/hyae103","DOIUrl":"10.1093/jjco/hyae103","url":null,"abstract":"<p><p>Cutaneous apocrine carcinoma is a rare skin cancer arising from apocrine sweat glands. Disease-specific treatments are required for cutaneous adnexal carcinomas due to their heterogeneous treatment responsiveness. This review reports on the epidemiology, diagnosis, pathological features, surgical management, and use of systemic therapies for cutaneous apocrine carcinoma. Diagnosing cutaneous apocrine carcinoma requires presenting with distinctive pathological features and excluding metastatic adenocarcinomas, particularly breast cancer. Clinical findings are essential to exclude metastatic adenocarcinomas, and immunohistochemistry can be used as an adjunctive tool to rule out other diseases. Wide local excision is the standard treatment for resectable cutaneous apocrine carcinomas. Prophylactic lymphadenectomy should be considered as a treatment option given the high incidence of lymph node metastasis. Generally, cutaneous apocrine carcinomas are resistant to chemotherapy and radiation therapy; however, adjuvant radiotherapy is recommended for high-risk patients. Radiation or systemic therapy is administered to patients with distant metastases or recurrence. The systemic therapeutic options include cytotoxic chemotherapy, hormonal therapy, targeted therapy, and immune checkpoint inhibitors. Given the lack of data on clinical prognosis and standardized treatments, further studies are needed to improve our understanding of cutaneous apocrine carcinomas.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1135-1140"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discontinuation and non-publication of randomized controlled trials on cervical cancer or precancer. 终止和不公布宫颈癌或癌前病变随机对照试验。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae096
Dongfang Lu, Xiaolin Chen, Yanmin Mu, Lingxiao Kong, Ling Zhang, Juan Li

Background: Research waste is a considerable problem in clinical trials, with nonpublication being a significant contributor. We aimed to determine the prevalence of discontinuation and nonpublication of randomized controlled trials (RCTs) on cervical cancer or precancer.

Methods: We searched ClinicalTrials.gov for registered RCTs investigating cervical cancer or precancer that started between January 2000 and December 2020. The primary and secondary outcomes were trial nonpublication and premature discontinuation, respectively. Publication status was determined by systematic searches of peer-reviewed journals using the PubMed and Scopus databases.

Results: A total of 113 RCTs met the inclusion criteria. Among the 85 trials completed before December 2020, 44 (51.8%) were prematurely discontinued and 40 (47.1%) were unpublished. A single-center design (61.4% vs. 34.1%, P = .012) and lack of external funding (59.1% vs. 36.6%, P = .038) were significantly associated with trial discontinuation. Large-scale (target sample size >400; 46.7% vs. 17.5%, P = .004) and externally funded trials (66.7% vs. 35.0%, P = .004) were more likely to be published. Multivariate logistic analysis revealed that a large sample size [odd ratio (OR): 4.125, 95% confidence interval (CI): 1.511-11.259, P = .006] and presence of external funding (OR: 3.714, 95% CI: 1.513-9.117, P = .004) were independent positive factors for trial publication.

Conclusion: A significant proportion of RCTs related to cervical cancer or precancer were discontinued early or remain unpublished, resulting in a waste of research resources.

背景:在临床试验中,研究浪费是一个相当大的问题,而未公开是其中一个重要原因。我们旨在确定有关宫颈癌或癌前病变的随机对照试验(RCT)终止和未公开的普遍程度:我们在 ClinicalTrials.gov 上搜索了 2000 年 1 月至 2020 年 12 月间开始的研究宫颈癌或癌前病变的注册 RCT。主要和次要结果分别为试验未发表和过早终止。通过使用 PubMed 和 Scopus 数据库对同行评审期刊进行系统检索来确定发表情况:共有 113 项研究性试验符合纳入标准。在2020年12月之前完成的85项试验中,有44项(51.8%)提前终止,40项(47.1%)未发表。单中心设计(61.4% vs. 34.1%,P = .012)和缺乏外部资助(59.1% vs. 36.6%,P = .038)与试验中止有显著相关性。大规模试验(目标样本量大于400;46.7% vs. 17.5%,P = .004)和外部资助试验(66.7% vs. 35.0%,P = .004)更有可能发表。多变量逻辑分析显示,样本量大[奇数比(OR):4.125,95% 置信区间(CI):1.511-11.259,P = .006]和有外部资助(OR:3.714,95% CI:1.513-9.117,P = .004)是试验发表的独立积极因素:结论:相当一部分与宫颈癌或癌前病变有关的研究性试验提前终止或仍未发表,造成了研究资源的浪费。
{"title":"Discontinuation and non-publication of randomized controlled trials on cervical cancer or precancer.","authors":"Dongfang Lu, Xiaolin Chen, Yanmin Mu, Lingxiao Kong, Ling Zhang, Juan Li","doi":"10.1093/jjco/hyae096","DOIUrl":"10.1093/jjco/hyae096","url":null,"abstract":"<p><strong>Background: </strong>Research waste is a considerable problem in clinical trials, with nonpublication being a significant contributor. We aimed to determine the prevalence of discontinuation and nonpublication of randomized controlled trials (RCTs) on cervical cancer or precancer.</p><p><strong>Methods: </strong>We searched ClinicalTrials.gov for registered RCTs investigating cervical cancer or precancer that started between January 2000 and December 2020. The primary and secondary outcomes were trial nonpublication and premature discontinuation, respectively. Publication status was determined by systematic searches of peer-reviewed journals using the PubMed and Scopus databases.</p><p><strong>Results: </strong>A total of 113 RCTs met the inclusion criteria. Among the 85 trials completed before December 2020, 44 (51.8%) were prematurely discontinued and 40 (47.1%) were unpublished. A single-center design (61.4% vs. 34.1%, P = .012) and lack of external funding (59.1% vs. 36.6%, P = .038) were significantly associated with trial discontinuation. Large-scale (target sample size >400; 46.7% vs. 17.5%, P = .004) and externally funded trials (66.7% vs. 35.0%, P = .004) were more likely to be published. Multivariate logistic analysis revealed that a large sample size [odd ratio (OR): 4.125, 95% confidence interval (CI): 1.511-11.259, P = .006] and presence of external funding (OR: 3.714, 95% CI: 1.513-9.117, P = .004) were independent positive factors for trial publication.</p><p><strong>Conclusion: </strong>A significant proportion of RCTs related to cervical cancer or precancer were discontinued early or remain unpublished, resulting in a waste of research resources.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1141-1149"},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Japanese journal of clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1